Hamodat Omar, Almuzainy Saif, Yahya Rand, Alzaatreh Razan, Haroon Samiullah, Koniali Salam
College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
J Saudi Heart Assoc. 2025 Mar 27;37(2):4. doi: 10.37616/2212-5043.1426. eCollection 2025.
Atrial fibrillation (AF) is a common comorbidity in patients undergoing mitral valve surgery (MVS), significantly increasing the risk of thromboembolism, heart failure, and mortality. Surgical ablation has recently been given a Class IA recommendation for concomitant MVS, reinforcing its role in restoring sinus rhythm and improving outcomes in this population. However, concerns about procedural complexity, extended operative time, and postoperative risks have limited its widespread adoption. This systematic review aims to synthesize evidence from recent randomized controlled trials to evaluate the safety and efficacy of surgical ablation for AF in patients undergoing MVS, addressing critical gaps in current clinical practice.
We systematically searched Scopus, PubMed, and Ovid up to December of 2024 for randomized controlled trials (RCTs) that investigated surgical ablation concomitant to mitral valve repair or replacement (MVR) as the intervention, compared to isolated MVR.
This review included 15 RCTs with 1219 patients (681 in the MVR + ablation group and 538 in the MVR-only group). Sinus rhythm restoration was significantly higher in the MVR + ablation group at discharge (64.7% vs. 18.8%), 6 months (62.5% vs. 22.4%), and 1 year (66.0% vs. 25.7%), indicating both immediate and sustained benefits. Short-term mortality rates were similar between groups (2.2% vs. 1.97%), while 1-year mortality was lower in the MVR + ablation group (5.43% vs. 5.91%). Pacemaker implantation rates were slightly higher in the MVR + ablation group, while stroke and thromboembolic events were rare and comparable between groups.
Surgical ablation combined with mitral valve surgery significantly improves sinus rhythm outcomes. While stroke and short-term mortality remain comparable between groups, one-year mortality was lower in the ablation group, warranting further investigation. Additionally, the increased pacemaker implantation rate in specific populations warrants tailored approaches.
心房颤动(AF)是二尖瓣手术(MVS)患者中常见的合并症,会显著增加血栓栓塞、心力衰竭和死亡风险。手术消融最近被给予IA类推荐用于同期MVS,强化了其在恢复窦性心律和改善该人群预后方面的作用。然而,对手术复杂性、手术时间延长和术后风险的担忧限制了其广泛应用。本系统评价旨在综合近期随机对照试验的证据,以评估MVS患者行AF手术消融的安全性和有效性,解决当前临床实践中的关键差距。
我们系统检索了截至2024年12月的Scopus、PubMed和Ovid,以查找将二尖瓣修复或置换(MVR)同期手术消融作为干预措施与单纯MVR进行比较的随机对照试验(RCT)。
本评价纳入了15项RCT,共1219例患者(MVR+消融组681例,单纯MVR组538例)。MVR+消融组出院时(64.7%对18.8%)、6个月时(62.5%对22.4%)和1年时(66.0%对25.7%)的窦性心律恢复率显著更高,表明有即时和持续的益处。两组短期死亡率相似(2.2%对1.97%),而MVR+消融组1年死亡率更低(5.43%对5.91%)。MVR+消融组起搏器植入率略高,而卒中及血栓栓塞事件罕见且两组相当。
手术消融联合二尖瓣手术可显著改善窦性心律结局。虽然两组间卒中和短期死亡率相当,但消融组1年死亡率更低,值得进一步研究。此外,特定人群中起搏器植入率增加需要采取针对性方法。